ArticleInternational journal of clinical oncology2026
Clinical efficacy and safety of second-line cabozantinib after first-line immune checkpoint inhibitor-based combinations in metastatic renal cell carcinoma: a multicenter retrospective study.
Atsuki Matsukawa et al.PubMed ↗Publisher ↗
No numbers read from the abstract.